NCT07866547Not yet recruiting
Off-line Adaptive Proton Therapy
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This prospective in-silico study evaluates a novel Off-line Adaptive Proton Therapy (o-APT) workflow for patients with oropharyngeal cancer receiving proton therapy. The study assesses whether automated image analysis, treatment plan adaptation, and quality assurance can identify and prepare treatment plan modifications more efficiently than current clinical practice, without affecting patient care.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 29 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- University Medical Center Groningen
- Diseases
- Head and neck cancer, Childhood cancers
- NCT number
- NCT07866547
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Oct 2026 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Oropharyngeal cancer patients
- Planned for curatively intended proton therapy
- Treated with definitive radiotherapy, chemoradiation, or bioradiation
- Provided informed consent according to Standard Follow-up Program (SFP) for using data for research
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.